natgillin/translations-raw huggingface dataset:
What you need to know before you take Aprovel
Što morate znati prije nego počnete uzimati Aprovel
The patient should be closely monitored, and the treatment should be symptomatic and supportive.
Bolesnika je potrebno pomno nadzirati, a liječenje treba biti potporno i simptomatsko.
Your doctor will normally advise you to stop taking Aprovel before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Aprovel.
Vaš će Vam liječnik obično preporučiti da prestanete uzimati Aprovel prije nego što zatrudnite ili čim saznate da ste trudni te će Vam savjetovati da uzmete neki drugi lijek umjesto lijeka Aprovel.
Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water).
Tablete treba progutati s dovoljnom količinom tekućine (npr. jednom čašom vode).
Aprovel with food and drink Aprovel can be taken with or without food.
Aprovel s hranom i pićem Aprovel se može uzeti s hranom ili bez nje.
If you accidentally miss a daily dose, just take the next dose as normal.
Ako slučajno zaboravite uzeti dnevnu dozu, uzmite sljedeću dozu kao što to obično i činite.
Therefore, this combination is not recommended (see section 4.4).
Ta se kombinacija, stoga, ne preporučuje (vidjeti dio 4.4).
Aprovel contains lactose.
Aprovel sadrži laktozu.
The predefined blood pressure goal was ≤ 135/85 mmHg.
Unaprijed definirani ciljni krvni tlak bio je ≤ 135/85 mmHg.
Plasma protein binding is approximately 96%, with negligible binding to cellular blood components.
Vezivanje za proteine plazme iznosi približno 96%, s neznatnim vezanjem za krvne stanice.
The terminal elimination half-life of irbesartan is 11-15 hours.
Terminalno poluvrijeme eliminacije irbesartana iznosi 11-15 sati.
56 x 1 tablets:
56 x 1 tableta:
An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment.
Pridruženo poboljšanje brzine glomerularne filtracije nije zabilježeno tijekom prva tri mjeseca liječenja.
If you forget to take Aprovel
Ako ste zaboravili uzeti Aprovel
The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.
Incidencija štetnih događaja nije bila povezana s dozom (unutar preporučenog raspona doza), spolom, dobi, rasom ni trajanjem liječenja.
What Aprovel is and what it is used for What you need to know before you take Aprovel How to take Aprovel
Što se nalazi u ovoj uputi Što je Aprovel i za što se koristi Što morate znati prije nego počnete uzimati Aprovel Kako uzimati Aprovel
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Drugo i treće tromjesečje trudnoće (vidjeti dijelove 4.4 i 4.6).
Biotransformatin
Biotransformacija
There was no evidence of mutagenicity, clastogenicity or carcinogenicity.
Nije bilo znakova mutagenosti, klastogenosti ni kancerogenosti.
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Nositelj odobrenja će periodička izvješća o neškodljivosti za ovaj lijek podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107.(c) stavkom 7. Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve children over 12 years, nine children between 6 and 12 years).
Od 23 djece, rezultati farmakokinetike za 21 dijete mogli su se usporediti s farmakokinetikom u odraslih (12 djece u dobi iznad 12 godina i 9 djece u dobi od 6 do 12 godina).
Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.
Trenutno dostupni podaci opisani su u dijelovima 4.8, 5.1 i 5.2, međutim, nije moguće dati preporuku o doziranju.
IDNT was a double blind, controlled, morbidity and mortality trial comparing Aprovel, amlodipine and placebo.
IDNT je bilo dvostruko slijepo, kontrolirano ispitivanje morbiditeta i mortaliteta u kojem su uspoređivani Aprovel, amlodipin i placebo.
SPECIAL STORAGE CONDITIONS Do not store above 30°C.
POSEBNE MJERE ČUVANJA Ne čuvati na temperaturi iznad 30ºC.
However, there was no difference in the half-life and accumulation of irbesartan.
Međutim, nije bilo razlika što se tiče poluvijeka i nakupljanja irbesartana.
No specific information is available on the treatment of overdose with Aprovel.
Nema dostupnih specifičnih podataka o liječenju predoziranja lijekom Aprovel.
F-75008 Paris - France
F-75008 Paris - Francuska
At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses.
U 24 sata snižavanje krvnog tlaka bilo je 60-70% vršnog dijastoličkog i sistoličkog odgovora pri preporučenim dozama.
There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses.
Nije bilo znakova abnormalne sistemske toksičnosti niti toksičnosti za ciljni organ pri klinički relevantnim dozama.
Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).
Pedijatrijska populacija: irbesartan je ispitivan u pedijatrijskoj populaciji u dobi od 6 do 16 godina, ali trenutni podaci nisu dostatni da bi podržali proširenje primjene na djecu, sve dok ne budu dostupni dodatni podaci (vidjeti dio 4.8, 5.1 i 5.2).
When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.
Kad su se analizirale individualne komponente primarne mjere ishoda, nisu zabilježeni učinci na sve uzroke smrtnosti, dok je zabilježen pozitivan trend u smanjenju terminalne faze bubrežne bolesti i značajno smanjenje u udvostručavanju serumskog kreatinina.
 Keep this leaflet.
Sačuvajte ovu uputu.
If the combination proves necessary, careful monitoring of serum lithium levels is recommended.
Ako je kombinacija neophodna, preporučuje se pažljiva kontrola serumske razine litija.
Results showed that Cmax, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily.
Rezultati su pokazali da su Cmax, AUC i brzine klirensa usporedivi s onima uočenim u odraslih bolesnika koji su uzimali 150 mg irbesartana na dan.
The doctor may advise a lower dose, especially when starting treatment in certain patients such as those on haemodialysis, or those over the age of 75 years.
Liječnik može preporučiti nižu dozu, posebice na početku liječenja određene skupine bolesnika kao što su bolesnici na hemodijalizi ili stariji od 75 godina.
If you get any of these symptoms or get short of breath, stop taking Aprovel and contact your doctor immediately.
Ako primijetite bilo koji od ovih simptoma ili osjetite nedostatak zraka, prestanite uzimati Aprovel i odmah se javite liječniku.
Reproductive system and breast disorders Uncommon: sexual dysfunction
Poremećaji reproduktivnog sustava i dojki Manje često: seksualna disfunkcija
In particular, they appeared less favourable in women and non-white subjects (see section 5.1).
Posebice je bio slabije izražen u žena i bolesnika koji nisu bijele rase (vidjeti dio 5.1).
Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for older people.
Iako za bolesnike starije od 75 godina treba razmotriti započinjanje terapije dozom od 75 mg, dozu obično nije potrebno prilagoditi u starijih osoba.
Therefore, the use of Aprovel is not recommended.
Stoga se ne preporučuje primjena lijeka Aprovel.
The usual recommended initial and maintenance dose is 150 mg once daily, with or without food.
Uobičajena preporučena početna doza i doza održavanja iznosi 150 mg jedanput na dan, s hranom ili bez nje.
It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II.
Očekuje se da blokira sve aktivnosti angiotenzina II posredovane AT1 receptorom, bez obzira na izvor ili put sinteze angiotenzina II.
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Učestalost nuspojava u nastavku teksta definira se na sljedeći način: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
dysgeusia
disgeuzija
In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.
U otvorenom razdoblju ovoga ispitivanja, u trajanju od 26 tjedana, najčešće opažene laboratorijske abnormalnosti bile su povećana koncentracija kreatinina (6,5%) i povišene vrijednosti CK u 2% djece koja su primila lijek.
Aprovel is indicated in adults for the treatment of essential hypertension.
Aprovel je indiciran za liječenje esencijalne hipertenzije u odraslih.
Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist.
Irbesartan je snažan, oralno aktivan, selektivni antagonist receptora angiotenzina II (tip AT1).
Irbesartan lowers blood pressure with minimal change in heart rate.
Irbesartan snižava krvni tlak uz minimalne promjene srčanog ritma.
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or allcause mortality.
Irbesartan značajno snižava relativni rizik u primarnoj kombiniranoj mjeri ishoda udvostručavanja serumskog kreatinina, terminalne faze bubrežne bolesti ili svih uzroka mortaliteta.
Aprovel is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Aprovel se ne preporučuje majkama koje doje, a Vaš liječnik može izabrati drugu terapiju ako želite dojiti, osobito ako se radi o dojenju novorođenčeta ili nedonoščeta.
2112 Veresegyház - Hungary
2112 Veresegyhaz - Mađarska
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka u promet.
No teratogenic effects were observed in the rat or rabbit.
Nisu zabilježeni teratogeni učinci u štakora ni kunića.
Activated charcoal may be useful in the treatment of overdose.
Za liječenje predoziranja može biti koristan aktivni ugljen.
As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.
Kao i kod bilo kojeg antihipertenziva, prekomjerni pad krvnog tlaka u bolesnika s ishemijskom kardiopatijom ili ishemijskom kardiovaskularnom bolešću može dovesti do infarkta miokarda ili moždanog udara.
Such conditions should be corrected before the administration of Aprovel.
Takva stanja treba korigirati prije primjene lijeka Aprovel.
Rebound hypertension has not been observed.
Nije zabilježena pojava veće (rebound) hipertenzije.
All of these changes were considered to be caused by the pharmacological action of irbesartan.
Sve navedene promjene uzrokovane su farmakološkim djelovanjem irbesartana.
There is no clinically important effect on serum uric acid or urinary uric acid secretion.
Nema klinički važnog učinka na mokraćnu kiselinu u serumu niti na urinarno izlučivanje mokraćne kiseline.
hyperkalaemia Nervous system disorders Common:
hiperkalijemija Poremećaji živčanog sustava Često:
Aprovel at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg.
Doza od 150 mg lijeka Aprovel jedanput na dan općenito osigurava bolju kontrolu krvnog tlaka u razdoblju od 24 sata nego doza od 75 mg.
No significant effects on the number of corpora lutea, implants, or live foetuses were observed.
Nije zabilježen značajan utjecaj na broj žutih tijela, broj implantacija niti broj živih fetusa.
As with similar medicines, rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan.
Kao i kod ostalih sličnih lijekova, zabilježeni su rijetki slučajevi alergijskih kožnih reakcija (osip, urtikarija), kao i lokalizirano oticanje lica, usnica i/ili jezika u bolesnika koji su uzimali irbesartan.
Irbesartan AUC and Cmax values were also somewhat greater in older subjects (≥ 65 years) than those of young subjects (18-40 years).
Vrijednosti AUC i Cmax irbesartana također su bile nešto veće u starijih ispitanika (≥ 65 godina) u usporedbi s mlađima (18-40 godina).
When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.
Prilikom upravljanja vozilima i strojevima potrebno je uzeti u obzir da se tijekom terapije mogu pojaviti omaglica i umor.
After withdrawal of therapy, blood pressure gradually returns toward baseline.
Nakon prekida liječenja, krvni tlak se postupno vraća na početne vrijednosti.
Aprovel is unlikely to affect your ability to drive or use machines.
Aprovel ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima i strojevima.
14 tablets 28 tablets 30 tablets 56 tablets 56 x 1 tablets 84 tablets 90 tablets 98 tablets
14 tableta 28 tableta 30 tableta 56 tableta 56 x 1 tableta 84 tableta 90 tableta 98 tableta
30 - 56 x 1 - 90 tablets:
30 - 56 x 1 - 90 tableta:
The usual dose is 150 mg once a day.
Uobičajena doza iznosi 150 mg jedanput na dan.
After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80%.
Nakon peroralne primjene irbesartan se dobro apsorbira: ispitivanja apsolutne bioraspoloživosti pokazala su vrijednosti od približno 60-80%.
No dosage adjustment is necessary in older people.
Stoga nije potrebna prilagodba doze u starijih osoba.
Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity (see section 5.3).
Primjena irbesartana nije utjecala na plodnost ispitivanih štakora i njihovog potomstva, do doza koje su inducirale prve znakove parentalne toksičnosti (vidjeti dio 5.3).
arthralgia, myalgia (in some cases associated with increased plasma creatine kinase levels), muscle cramps
artralgija, mialgija (u nekim slučajevima povezana s povećanom koncentracijom kreatin kinaze u plazmi), grčevi mišića
You may need to have blood checks if you take: potassium supplements salt substitutes containing potassium potassium-sparing medicines (such as certain diuretics) medicines containing lithium
Možda ćete trebati obaviti pretrage krvi ako uzimate: nadomjeske kalija nadomjeske soli koji sadrže kalij lijekove koji čuvaju kalij (kao što su neki diuretici) lijekove koji sadrže litij
dizziness, orthostatic dizziness*
omaglica, ortostatska omaglica*
The maximal blood pressure lowering effect should be reached 4-6 weeks after beginning treatment.
Maksimalan učinak na sniženje krvnog tlaka trebao bi se postići za 4-6 tjedana nakon početka liječenja.
Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose.
Nije zabilježen utjecaj na plodnost i reproduktivnu učinkovitost u istraživanjima na mužjacima i ženkama štakora, čak ni pri oralnim dozama irbesartana koje su uzrokovale određenu parentalnu toksičnost (doze od 50 do 650 mg/kg/dnevno), uključujući mortalitet pri najvišim dozama.
The usual dose is 150 mg once a day (two tablets a day).
Uobičajena doza iznosi 150 mg jedanput na dan (dvije tablete na dan).
Aprovel belongs to a group of medicines known as angiotensin-II receptor antagonists.
Aprovel pripada skupini lijekova koja se naziva antagonisti receptora angiotenzina II.
While this is not documented with Aprovel, a similar effect should be anticipated with angiotensin-II receptor antagonists.
Iako to još nije potvrđeno za Aprovel, sličan učinak može se očekivati s antagonistima receptora angiotenzina II.
hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, anaphylactic shock Metabolism and nutrition disorders Not known:
reakcije preosjetljivosti kao što su angioedem, osip, urtikarija, anafilaktička reakcija, anafilaktički šok Poremećaji metabolizma i prehrane Nepoznato:
Concomitant food intake does not significantly influence the bioavailability of irbesartan.
Istodobno uzimanje s hranom ne utječe značajno na bioraspoloživost irbesartana.
Patients were titrated from 75 mg to a maintenance dose of 300 mg Aprovel, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.
Bolesnici su titrirani od 75 mg do doze održavanja od 300 mg lijeka Aprovel, od 2,5 mg do 10 mg amlodipina ili placeba do granice podnošljivosti.
Angiotensin-II is a substance produced in the body which binds to receptors in blood vessels causing them to tighten.
Angiotenzin II je tvar koja se stvara u tijelu i koja se veže na receptore u krvnim žilama te uzrokuje njihovo sužavanje.
Renal impairment and kidney transplantation: when Aprovel is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Oštećena funkcija bubrega i transplantacija bubrega: kad Aprovel uzimaju bolesnici s oštećenom funkcijom bubrega, preporučuje se periodički kontrolirati serumske razine kalija i kreatinina.
It is unknown whether irbesartan or its metabolites are excreted in human milk.
Nije poznato izlučuju li se irbesartan ili njegovi metaboliti u majčino mlijeko u ljudi.
In patients insufficiently controlled with 150 mg once daily, the dose of Aprovel can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).
U bolesnika u kojih se bolest ne može dostatno kontrolirati dozom od 150 mg jedanput na dan, doza lijeka Aprovel može se povećati na 300 mg ili se mogu dodati drugi antihipertenzivi (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Aprovel (see section 4.5).
Pokazalo se da dodavanje diuretika poput hidroklorotiazida ostvaruje aditivan učinak s lijekom Aprovel (vidjeti dio 4.5).
Because no information is available regarding the use of Aprovel during breast-feeding, Aprovel is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Budući da nema dostupnih podataka o upotrebi lijeka Aprovel tijekom dojenja, ne preporučuje se njegova primjena tijekom dojenja i prednost treba dati drugoj terapiji s ustanovljenim boljim profilom sigurnosti primjene, osobito kada se doji novorođenče ili nedonošče.
In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.
In vitro ispitivanja upućuju da se irbesartan primarno oksidira pomoću enzima CYP2C9 citokroma P450, dok izoenzim CYP3A4 ima neznatan učinak.
Regression to normoalbuminuria (< 30 mg/day) was more frequent in the Aprovel 300 mg group (34%) than in the placebo group (21%).
Regresija do normoalbuminurije (< 30 mg/dan) bila je češća u skupini koja je primala lijek Aprovel u dozi od 300 mg (34%) nego u skupini koja je primala placebo (21%).
How to take Aprovel
Kako uzimati Aprovel
Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded.
Epidemiološki podaci koji se odnose na rizik od teratogenog učinka nakon izloženosti ACE inhibitorima tijekom prvog tromjesečja nisu bili dostatni za donošenje zaključaka.
Aprovel prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
Aprovel sprječava vezanje angiotenzina II na te receptore uzrokujući opuštanje krvnih žila i sniženje krvnog tlaka.
Aprovel is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Aprovel se ne preporučuje u ranoj trudnoći te se ne smije uzimati nakon trećeg mjeseca trudnoće jer može ozbiljno naškoditi Vašem djetetu ako ga uzimate u tom razdoblju.
The following table presents the adverse drug reactions that were reported in placebo-controlled trials in which 1,965 hypertensive patients received irbesartan.
Sljedeća tablica prikazuje nuspojave prijavljene u placebom kontroliranim ispitivanjima, u kojima je 1965 hipertenzivnih bolesnika primalo irbesartan.
Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use machines.
Na temelju farmakodinamičkih svojstava, irbesartan ne bi trebao utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
Close monitoring of serum potassium in patients at risk is recommended (see section 4.5).
Preporučuje se česta kontrola serumskog kalija u rizičnih bolesnika (vidjeti dio 4.5).
Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
Dodatne informacije o interakcijama irbesartana: u kliničkim ispitivanjima hidroklorotiazid nije utjecao na farmakokinetiku irbesartana.
In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%).
U trotjednoj dvostruko slijepoj fazi randomiziranog kliničkog ispitivanja u koju je bilo uključeno 318 djece i adolescenata s hipertenzijom u dobi od 6 do 16 godina pojavile su se sljedeće nuspojave: glavobolja (7,9%), hipotenzija (2,2%), omaglica (1,9%), kašalj (0,9%).
Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Aprovel (see section 4.4).
Prethodno liječenje visokim dozama diuretika može dovesti do smanjenja volumena i rizika od pojave hipotenzije prilikom uvođenja terapije lijekom Aprovel (vidjeti dio 4.4).
Some undesirable effects have been reported since marketing of Aprovel.
Neke nuspojave prijavljene su otkad je Aprovel na tržištu.
As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population (see section 5.1).
Kao što je zapaženo kod inhibitora angiotenzin konvertirajućeg enzima, irbesartan i ostali antagonisti angiotenzina očigledno su manje učinkoviti u snižavanju krvnog tlaka u bolesnika crne rase nego u drugih rasa, vjerojatno zbog veće prevalencije stanja niskog renina u populaciji hipertoničara crne rase (vidjeti dio 5.1).
In rabbits, abortion or early resorption were noted at doses causing significant maternal toxicity, including mortality.
Pobačaj ili rana resorpcija opaženi su u kunića pri dozama koje su uzrokovale značajnu toksičnost kod majke, uključujući i smrtnost.
The selective antagonism of the angiotensin-II (AT1) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration.
Selektivni antagonizam receptora angiotenzina II (AT1) za ishod ima povećanje razine renina u plazmi i razine angiotenzina II te snižavanje koncentracije aldosterona u plazmi.